Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
about
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.Super-compact treatment with a high dose of moxifloxacin in patients with drug-resistant tuberculosis and its resistance mechanismsPharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary TuberculosisMoxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.Rifapentine for the treatment of latent tuberculosis.Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
P2860
Q24202081-25EC3F7D-44A5-40FB-A351-02FC97B5EFDEQ34519945-22249117-D2C0-431C-BEEE-38AB38A2A928Q35159676-3A3FD561-0860-4990-8CA0-1E6B0B286B75Q35197257-AA1186D2-115E-4CD6-B0FA-18F9A31053E2Q36012300-D2C08D75-87F7-4701-93AC-712C4DDE2D2BQ37544479-96C36E63-C3AF-47D0-BBC0-A4776771E7F9Q38754367-0D953E1D-9E77-41AA-8EE2-001AD83D5293Q38933165-AFE7EF3B-9813-4A1D-BFCA-8BA539A54719Q38973113-6A26B0D6-A63F-46F9-860A-0DE8CE7A25E3Q39456569-E9850517-E902-452A-A55E-7EB0575061BEQ40095703-69ECAD21-FC96-48EF-BB36-182EDE438B04Q41454109-E936D56C-7F98-4468-A82C-D858406BAD8AQ46650295-7470E36D-E86F-4661-BF31-6DB841C18C4BQ52584725-A18CB779-E7E5-4546-A535-704DC03B7DC2
P2860
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Moxifloxacin population pharma ...... mittent high-dose rifapentine.
@en
type
label
Moxifloxacin population pharma ...... mittent high-dose rifapentine.
@en
prefLabel
Moxifloxacin population pharma ...... mittent high-dose rifapentine.
@en
P2093
P2860
P50
P356
P1476
Moxifloxacin population pharma ...... mittent high-dose rifapentine.
@en
P2093
Amina Jindani
Danelle van As
Sandra Meredith
Simbarashe P Zvada
Thomas Harrison
Ulrika S H Simonsson
P2860
P304
P356
10.1128/AAC.00404-12
P407
P577
2012-05-14T00:00:00Z